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Introduction
Zinc (Zn2þ) is an essential trace element, serving as a co-
factor for 10 to 15% of proteins encoded within the human
genome.1 It is acknowledged as an extracellular signalling
molecule in glycinergic and GABAergic neurones, and is
released into the synaptic cleft following excitation.2,3
Zn2þ is concentrated in atherosclerotic plaques and released
from damaged epithelial cells, and is released from platelets
along with their α-granule cargo following collagen stimula-
tion.4 Therefore, increased concentrations of unbound or
labile (free) Zn2þ are likely to be present at areas of haemos-
tasis, and may be much higher in the microenvironment of a
growing thrombus. Zn2þ plays a role in haemostasis by
contributing to wound healing,5 and regulating coagulation,
for example, as a co-factor for factor XII.6 Labile Zn2þ acts as a
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Abstract Background Zinc (Zn2þ) is an essential trace element that regulates intracellular
processes in multiple cell types. While the role of Zn2þ as a platelet agonist is known,
its secondary messenger activity in platelets has not been demonstrated.
Objectives This article determines whether cytosolic Zn2þ concentrations ([Zn2þ]i)
change in platelets in response to agonist stimulation, in a manner consistent with
a secondarymessenger, andcorrelates theeffects of [Zn2þ]i changesonactivationmarkers.
Methods Changes in [Zn2þ]i were quantiﬁed in Fluozin-3 (Fz-3)-loaded washed,
human platelets using ﬂuorometry. Increases in [Zn2þ]i were modelled using Zn
2þ-
speciﬁc chelators and ionophores. The inﬂuence of [Zn2þ]i on platelet function was
assessed using platelet aggregometry, ﬂow cytometry and Western blotting.
Results Increases of intra-platelet Fluozin-3 (Fz-3) ﬂuorescence occurred in response to
stimulation by cross-linked collagen-related peptide (CRP-XL) or U46619, consistent with a
rise of [Zn2þ]i. Fluoresence increaseswereblockedby Zn
2þ chelators andmodulators of the
platelet redox state, and were distinct from agonist-evoked [Ca2þ]i signals. Stimulation of
platelets with the Zn2þ ionophores clioquinol (Cq) or pyrithione (Py) caused sustained
increases of [Zn2þ]i, resulting in myosin light chain phosphorylation, and cytoskeletal re-
arrangements whichwere sensitive to cytochalasin-D treatment. Cq stimulation resulted in
integrin αIIbβ3 activation and release of dense, but not α, granules. Furthermore, Zn2þ-
ionophores induced externalization of phosphatidylserine.
Conclusion These data suggest that agonist-evoked ﬂuctuations in intra-platelet Zn2þ
couple to functional responses, in a manner that is consistent with a role as a secondary
messenger. Increased intra-platelet Zn2þ regulates signalling processes, including shape
change, αIIbβ3 up-regulation and dense granule release, in a redox-sensitive manner.
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platelet agonist, being able to induce tyrosine phosphoryla-
tion, integrin αIIbβ3 activation and aggregation at high con-
centrations, while potentiating platelet responses to other
agonists at lower concentrations.7 Zn2þ is directly linked to
platelet function in vivo, as dietary Zn2þ deﬁciency of
humans or rodents manifests with a bleeding phenotype
that reverses with Zn2þ supplementation.
Labile, protein-bound and membrane-bound, Zn2þ pools
are found within multiple cell types, including immune cells
and neurones. These pools are inter-changeable, allowing
increases in the bioavailability of Zn2þ to Zn2þ-sensitive
proteins following signalling-dependent processes. In this
manner, Zn2þ is acknowledged to behave as a secondary
messenger.8 In nucleated cells, Zn2þ is released from intracel-
lular granules into the cytosol via Zn2þ transporters, or from
Zn2þ-binding proteins such as metallothioneins, following
engagement of extracellular receptors. For example, a role
for Zn2þ as a secondary messenger has been shown in mast
cells, where engagement of the FCε receptor I results in rapid
increases in intracellular Zn2þ (Zn2þ]i). This ‘zinc wave’ mod-
ulates transcription of cytokines, and affects tyrosine phos-
phatase activity.8 Zn2þ also acts as a secondary messenger in
monocytes,wherestimulationwith lipopolysaccharide results
in increases in [Zn2þ]i, suggestive of a role in transmembrane
signalling.9 Agonist-evoked changes of [Zn2þ]i modulate sig-
nallingproteins (i.e. proteinkinaseC [PKC], calmodulin-depen-
dent protein kinase II [CamKII] and interleukin receptor-
associated kinase) in a similar manner to calcium (Ca2þ)-
dependent processes.4,8,10 While the role of Zn2þ as
a secondarymessenger innucleatedcellshasgathered support
in recent years, agonist-dependent regulation of [Zn2þ]i in
platelets during thrombosis has yet to be demonstrated.
Here, we utilize Zn2þ-speciﬁc ﬂuorophores, chelators and
ionophores to investigate the role of [Zn2þ]i ﬂuctuations in
platelet behaviour.We show that agonist-evoked elevation of
[Zn2þ]i regulates platelet shape change, dense granule
release and phosphatidylserine (PS) exposure. Theseﬁndings
indicate a role for Zn2þ as a secondarymessenger, whichmay
have implications for the understanding of platelet signalling
pathways involved in thrombosis during adverse cardiovas-
cular events.
Experimental Procedures
Materials: Fluozin-3-AM (Fz-3, Zn2þ indicator) and Fluo-4-AM
(Ca2þ indicator) were from Invitrogen (Paisley,
United Kingdom). Z-VAD (pan-caspase inhibitor) was from
R&D Systems (Abingdon, United Kingdom). Primary anti-
vasodilator-stimulated phosphoprotein (VASP) (Ser157) and
anti-myosin light chain (MLC) (Ser19) antibodies were from
Cambridge Bioscience (Cambridge, United Kingdom), and
ﬂuorescently conjugated procaspase-activating compound
1 (PAC-1), CD62P and CD63 antibodies were from BD Bios-
ciences (Oxford, United Kingdom). Cross-linked collagen-
related peptide (CRP-XL; glycoprotein VI [GpVI] agonist)
was from Professor Richard Farndale (Cambridge,
United Kingdom), U46619 (thromboxane [TP]α receptor
agonist)was fromTocris (Bristol, United Kingdom), thrombin
(protease-activated receptor [PAR] agonist) was from Sigma
Aldrich (Poole, United Kingdom) and cytochalasin-D (Cyt-D,
actin polymerization inhibitor) was from AbCam (Cam-
bridge, United Kingdom). Clioquinol (Cq, Zn2þ ionophore,
C9H5ClINO, KdZn: 107 M, KdCa: 10-4.9 M), pyrithione (Py,
Zn2þ ionophore, C10H8N2O2S2, KdZn: 107 M, KdCa: 10-4.9 M),
A23187 (Ca2þ ionophore, C29H37N3O6), N,N,N′,N′-Tetrakis(2-
pyridylmethyl)ethylenediamine (TPEN, Zn2þ chelator, KdZn:
2.6  1016 M, KdCa: 4.4  105 M,11–14), dimethyl-bis-
(aminophenoxy)ethane-tetraacetic acid (DM-BAPTA)-AM
(C34H40N2O18, KdZn: 7.9  109 M, KdCa: 110  109
M,11–14) and membrane permeant anti-oxidizing proteins,
polyethylene glycol-superoxide dismutase (PEG-SOD) and
PEG-catalase (CAT) were from Sigma Aldrich. Unless stated,
all other reagents were from Sigma Aldrich.
Preparation of washed human platelets: This study was
approved by the Research Ethics Committee at Anglia Ruskin
University and informed consent was obtained in accordance
with the Declaration of Helsinki. Blood was donated by
healthy human volunteers, free frommedication for 2weeks.
Blood was collected into 11 mM sodium citrate and washed
platelets were prepared as described previously.7 Unless
otherwise stated, to isolate the mechanisms of Zn2þ ﬂuctua-
tions from other cation-speciﬁc effects, experiments were
performed in the absence of extracellular Ca2þ.
Cation mobilisation studies: For studies of [Zn2þ]i or
[Ca2þ]i mobilization, platelet-rich plasma was loaded with
Fz-3 (2 µM, 30 minutes, 37°C), or Fluo-4 (2 µM, 30 minutes,
37°C). Fz-3 is responsive to Zn2þ in the nM range and is not
signiﬁcantly affected by Ca2þ.15 Platelets were collected by
centrifugation (350  g, 15 minutes), re-suspended in Ca2þ-
free Tyrode’s buffer (in mM: 140 NaCl, 5 KCl, 10 HEPES, 5
glucose, 0.42 NaH2PO4, 12 NaHCO3, pH 7.4) and rested at 37°
C for 30 minutes prior to use. Fluorescence was monitored
using a Fluoroskan Ascent ﬂuorometer (ThermoScientiﬁc,
United Kingdom) using 488 nm and 538 nm excitation and
emission ﬁlters, respectively. Washed Fz-3 or Fluo-4 loaded
platelet suspensions were treated with ionophores or che-
lators to calibrate Rmax or Rmin values (►Supplementary
Fig. S1, available in the online version). Results are expressed
as an increase of background-corrected ﬂuorescence at each
time point relative to baseline: (F-Fbackground)/F0-Fbackground).
Optical aggregometry: Aggregometry was performed with
washed platelet suspensions under stirring conditions at 37°C
in an AggRam light transmission aggregometer (Helena Bios-
ciences, Gateshead, United Kingdom).7 Aggregation traces
were acquired using a proprietary software (Helena Bios-
ciences) and analysed within GraphPad Prism (Version 6.03).
Confocal microscopy: Images of platelets adhering to
coated ﬁbrinogen coverslips (100 µM) were acquired using
a LSM510/Axiovert laser scanning confocal microscope with
60 oil NA1.45 objective (Zeiss, United Kingdom). Surface
coverage of DIOC6-stained platelets was quantiﬁed using
ImageJ (v1.45, National Institutes of Health, Bethesda, Mary-
land, United States).
Western blotting: Western blotting was performed as
described previously.7 Brieﬂy, polyvinylidene diﬂuoride
membranes were incubated with MLC (1:400) or VASP
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(Ser157, 1:400) primary antibodies, and horseradish perox-
idase-conjugated secondary antibodies (1:7,500).
Flow cytometry: Washed platelet suspensions were incu-
bated with ﬂuorescently conjugated antibodies targeting
markers of platelet activation: PAC-1 (αIIbβ3 activation),
CD62P (α granule release) and CD63 (dense granule release).
Antibody binding following agonist or ionophore stimulation
was assessed using an Accuri C6 ﬂow cytometer (BD
Biosciences).
Data analysis: Maximum and minimum aggregation and
F/F0 values were calculated using Microsoft Excel. Western
blots were analysed using ImageJ. Data were analysed in
GraphPad Prism by two-way analysis of variance followed by
Tukey’s post hoc test. Signiﬁcance is denoted as p < 0.001,
p < 0.01 or p < 0.05.
Results
[Zn2þ]i ﬂuctuations coordinate receptor stimulation with sig-
nalling responses in nucleated cells.8 To investigate whether
intra-platelet Zn2þ ﬂuctuates during activation, agonist-
evoked changes of [Zn2þ]i were monitored in washed platelet
suspensions, loaded with the Zn2þ-speciﬁc ﬂuorophore, Fz-3.
Stimulation with conventional platelet agonists CRP-XL and
U46619 induced rapid, dose-dependent increases of ﬂuores-
cence peaking after approximately 2 minutes, consistent with
increases in [Zn2þ]i. At 6 minutes, 1 µg/mL CRP-XL or 10 µM
U46619 stimulation increased F/F0 to 2.0  0.1 and 1.2  0.1
AU, respectively (compared with 0.9  0.2 AU for the vehicle
control, p < 0.05,►Fig. 1A, B). Conversely, thrombin stimula-
tion did not elevate Fz-3 ﬂuorescence (►Fig. 1C). These data
indicate that platelet activation via GpVI and TP, but not via
PARs, leads to signalling responses that result in the elevation
of [Zn2þ]i, in a similar manner to agonist-evoked increases in
[Ca2þ]i. Inclusion of 2 mM CaCl2 in the extracellular medium
did not signiﬁcantly affect agonist-evoked responses
(►Supplementary Fig. S2, available in the online version).
Experiments were performed to conﬁrm the speciﬁcity of
ﬂuorescence ﬂuctuations for Zn2þ. Platelets were pre-treated
with the intracellular Zn2þ-speciﬁc chelator TPEN (50 µM)
prior to stimulation with 1 µg/mL CRP-XL. Fz-3 responses
were reduced to 1.1  0.1 AU, compared with of 2.0  0.1
AU for CRP-XL stimulation alone (p < 0.05, ►Fig. 2A). Inter-
estingly, treatment with DM-BAPTA (10 µM), a non-speciﬁc
cation chelator, led to a similar reduction (to 1.0  0.1 AU,
p < 0.05). Abrogation of Fz-3 ﬂuorescence was also observed
followingstimulationwithU46619 (10 µg/mL),whereTPENor
DM-BAPTA treatment reduced F/F0 plateau levels from
1.2  0.1 to 0.8  0.1 AU and 1.0  0.1 AU, respectively
(p < 0.05, ►Fig. 2B). Further experiments were performed
to investigate the inﬂuence of cation chelation on [Ca2þ]i
ﬂuctuations using Fluo-4-loaded platelets. As previously
demonstrated, CRP-XL- and U46619-induced Ca2þ signals
were absent following BAPTA treatment (F/F0 signals were
reduced from 1.6  0.2 to 0.8  0.1 AU, and from 1.4  0.1 to
0.9 þ 0.0AU, forCRP-XL andU46619stimulation, respectively,
p < 0.05, ►Fig. 2D, E). However, Fluo-4 ﬂuorescence was not
signiﬁcantly affected by TPEN treatment (1.5  0.2 and
1.2  0.1 AU for CRP-XL and U46619, respectively, ns) indicat-
ing that TPENdoesnot chelate [Ca2þ]i, and that Fz-3 signals are
attributable to [Zn2þ]i with no inﬂuence from other cations.
Furthermore, these data demonstrate that ﬂuctuations in
[Zn2þ]i do not affect agonist-evoked Ca2þ signals.
Agonist-evoked [Zn2þ]i increasesmay result from release of
membrane-bound intracellular stores or by liberation from
metal-binding proteins (e.g. metallothioneins) in response to
redox-mediatedmodiﬁcations to thiol groups.16 To investigate
the nature of the Zn2þ source, platelets were treated with
membrane-permeant anti-oxidizing proteins PEG-SOD and
PEG-CAT,17 and CRP-XL-evoked [Zn2þ]i ﬂuctuations were
monitored. PEG-SOD and PEG-CAT both abolished CRP-XL-
induced increases of Fz-3 ﬂuorescence, indicating redox-
dependent modulation of Zn2þ release (PEG-SOD and PEG-
CAT reduced F/F0 plateaus following 1 µg/mL CRP-XL treat-
ment from 2.0  0.1 to 1.2  0.1 AU and 1.3  0.1 AU, respec-
tively, p < 0.05, ►Fig. 2A). This is consistent with published
data showing a greater capacity for GpVI to inﬂuence redox
signalling than other receptors.18 Similarly, PEG-SODand PEG-
CATabolishedU46619-induced [Zn2þ]i responses (to 1.0  0.0
and 1.1  0.0 AU, respectively, following 10 µM U46619 sti-
mulation, p < 0.05, ►Fig. 2B). PEG-SOD and PEG-CAT did not
affect CRP-XL- or U46619-mediated Fluo-4 ﬂuorescence, sug-
gesting that [Zn2þ]i but not [Ca2þ]i signals are regulated by
redox-sensitive processes.
Fig. 1 Agonist-dependent platelet activation via GpVI or TP, but not PARs elevates [Zn2þ]i. Fz-3-labelled washed human platelets were
stimulated by CRP-XL (A), U46619 (B) or thrombin (C) and [Zn2þ]i ﬂuctuations were monitored over 6 minutes using ﬂuorometry. (A) Fz-3
responses to○ 1 µg/mL, & 0.3 µg/mL,~ 0.1 µg/mL, } 0.03 µg/mL CRP-XL or• vehicle (DMSO). (B) Fz-3 responses to○ 10 µM, & 3 µM,~
1 µM,} 0.3 µMU46619 or• vehicle (DMSO). (C) Fz-3 responses to,○ 1 U/mL, & 0.3 U/mL,~ 0.1 U/mL,}0.03 U/mL thrombin or• vehicle
(DMSO). Data are mean  standard error of the mean (SEM) from at least 8 independent experiments. Signiﬁcance is denoted as p < 0.001,
p < 0.01 or p < 0.05.
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Further experiments were performed to resolve the rela-
tionship between the platelet redox state and [Zn2þ]i ﬂuc-
tuations. Treatment with H2O2 mimics increases in platelet
reactive oxygen species (ROS).19 H2O2 increased both [Ca2þ]i
and [Zn2þ]i (F/F0 plateaus were 1.8 þ 0.3 AU following H2O2
[10 µM] stimulation of Fz3-loaded platelets, compared with
0.9  0.1 AU for vehicle-treated platelets, while H2O2 sti-
mulation increased Fluo-4 ﬂuorescence from 0.9  0.1 to
1.4  0.1 AU, p < 0.05, ►Fig. 2C, F). H2O2-mediated [Zn2þ]i
increases were abrogated with PEG-SOD or PEG-CAT, while
[Ca2þ]i was unaffected (►Fig. 2E, F). These data support a role
for the platelet redox state in regulating [Zn2þ]i ﬂuctuations.
Having demonstrated that intra-platelet Zn2þ rises in
response to agonist stimulation, we further examined the
Fig. 2 Agonist-dependent intracellular zinc ([Zn2þ]i) ﬂuctuations are sensitive to the platelet redox state. Platelets were loadedwith Fz-3 (A, B, C), or Fluo-4
(D, E, F) and stimulated with CRP-XL (1 µg/mL, ○, A, D), U46619 (10 µM, ○ B, E) or H2O2 (10 µM, ○, C, F), during which changes in ﬂuorescence were
monitored. Where indicated, platelets were pre-treated with TPEN (5, 50 µM), DM-BAPTA (}, 10µM), PEG-SOD (&, 30 U/mL), PEG-CAT (~, 300 U/mL) or
vehicle (DMSO),•). Data aremean  standard error of themean (SEM) fromat least 5 independent experiments. Signiﬁcance is denoted as p < 0.001,p < 0.01 or p < 0.05.
Thrombosis and Haemostasis Vol. 119 No. 1/2019
Agonist-Evoked Intra-Platelet Zinc Fluctuations Ahmed et al. 131
inﬂuence of [Zn2þ]i on platelet responses. We hypothesized
that liberation of Zn2þ from intracellular stores (such as
plateletα-granules20) using speciﬁc ionophoreswould result
in increased [Zn2þ]i, in a similar manner A23187-evoked
Ca2þ responses.21 Zn2þ ionophores Cq and Py have pre-
viously been used to model [Zn2þ]i increases in nucleated
cells.22–24 We utilized these reagents to model agonist-
evoked [Zn2þ]i increases in washed platelet suspensions.
Stimulation with Cq or Py produced large elevations of
[Zn2þ]i, with F/F0 plateaus of 7.9  0.5 and 3.3  0.3 AU,
respectively (p < 0.05, ►Fig. 3A, B). The extent of [Zn2þ]i
increase was greater than that observed following CRP-XL
stimulation, suggesting that liberation from stores is not the
principal means bywhich [Zn2þ]i increases following agonist
stimulation. Zn2þ ionophore-dependent Fz-3 ﬂuorescence
increases were sensitive to pre-treatment with TPEN or
BAPTA, consistent with a role for Cq or Py increasing
[Zn2þ]i (►Fig. 3A, B). However, [Zn2þ]i signals were not
inﬂuenced by PEG-SOD or PEG-CAT, demonstrating that
ionophore-induced [Zn2þ]i release is not redox sensitive.
Cq or Py stimulation did not affect Fluo-4 ﬂuorescence
(►Fig. 3D, E), indicating that Zn2þ ionophores have a negli-
gible afﬁnity for Ca2þ. A23187 increased Fluo-4 ﬂuorescence
(from 0.9  0.1 to 5.8  0.9 AU after 6 minutes, p < 0.05,
►Fig. 3F), but had no effect on Fz-3 ﬂuorescence (►Fig. 3C),
demonstrating that Fz-3 ﬂuorescence is not affected by
changes in [Ca2þ]i. In a similar manner to agonist-dependent
Ca2þ signalling, A23187-dependent [Ca2þ]i increases were
abrogated by BAPTA, but were unaffected by TPEN. Thus,
Fluo-4 ﬂuorescence is not inﬂuenced by Zn2þ.
Our data conﬁrm that platelet [Zn2þ]i increases can be
modelled using the Zn2þ ionophores Cq and Py. Next, we
examined the inﬂuence of increases in [Zn2þ]i on platelet
aggregation. High concentrations of Cq (300 µM) resulted in
an initial decrease in light transmission, followed by a
substantial increase, consistent with shape change and
aggregation. Platelet aggregates were present following
visual inspection of test cuvettes at the end of each experi-
ment (not shown). The extent of Cq-induced aggregation
(300 µM, 27.8  5.0%) was lower than that for A23187
(300 µM, 70.2  8.6%, p < 0.05, ►Fig. 4A, B). Treatment
with lower concentrations of Cq (30 µM) resulted in shape
change only, with no progression to aggregation. Py stimula-
tion did not cause aggregation but did result in shape change
(►Fig. 4A–C). Response to Py were biphasic, with intermedi-
ate concentrations (10–30 µM) resulting in shape change,
and higher concentrations having no effect.
The degree of shape change was quantiﬁed by calculating
the lowest light transmission during ionophore-induced
aggregation (denoted minimum aggregation, %). Shape
change following Cq or A213817 treatment was comparable
(minimum aggregation for 30 µM Cq or Py was –13.3  2.9
and –27.5  2.2%, respectively, compared with –15.1  2.7%
for 30 µM A23187, ns, ►Fig. 4C). These data are consistent
with a role for [Zn2þ]i in regulating cytoskeletal changes in a
similar manner to [Ca2þ]i-induced shape change.
To conﬁrm that the changes in light transmission were a
biological, rather than chemical phenomenon, we took a
pharmacological approach by pre-treating platelets with the
actin polymerization inhibitor Cyt-D prior to ionophore sti-
mulation.Cyt-DabrogatedCq-, Py- andA23187-inducedshape
change, consistent with a genuine biological effect. The mini-
mum aggregation for Cyt-D treated and untreated platelets
were –5.7  2.1 and –16.7  1.9%, respectively, following Cq
stimulation, –9.1  1.9 and –33.2  2.4, respectively, follow-
ing Py stimulation, and –3.7  1.4 and –13.0  1.8%,
Fig. 3 Treatment of platelets with Zn2þ ionophores clioquinol (Cq) or pyrithione (Py) elevates [Zn2þ]i, but not [Ca
2þ]i. Washed platelet
suspensions were loaded with Fz-3 (A, B, C), or Fluo-4 (D, E, F) and stimulated with Cq (○, 300 µM, A,D), Py (○, 300 µM, B, E) or A23187 (○, C, F).
Where indicated, platelets were pre-treated with (TPEN) (50 µM,5), DM-BAPTA (10 µM,}), PEG-SOD (30 U/mL,&), PEG-CAT (300 U/mL,~), or
vehicle (DMSO),•. Data are mean  standard error of the mean (SEM) from at least 6 independent experiments. Signiﬁcance is denoted asp < 0.001, p < 0.01 or p < 0.05.
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respectively, following A23187 stimulation (30 µM, p < 0.05,
►Fig. 5A, B). Pre-treatment of platelets with TPEN abrogated
Cq- or Py-induced shape change but had no effect on A23187
treatment (minimum aggregation following TPEN treatment
was –4.9  1.2, –11.1  2.3 and –17.9  2.6% for Cq, Py and
A23817, respectively, p < 0.05, ►Fig. 5A, B). These data are
consistent with a role for [Zn2þ]i in regulating cytoskeletal re-
arrangements. The resistance of A23187-induced shape
change to TPEN treatment suggests that the contribution of
Ca2þ signals to cytoskeletal re-arrangement occurs
Fig. 4 Stimulation of platelets with Zn2þ ionophores leads to shape change. (A) Washed platelet suspensions were stimulated with different
concentrations of clioquinol (Cq), pyrithione (Py) or A23187 during which changes in light transmissionweremonitored using optical aggregometry. Initial
downward deﬂections indicate a reduction in light transmission that are consistent with shape change. Subsequent upward deﬂections indicate increases
in light transmission, consistent with platelet aggregation. Themaximum (B) and minimum (C) extent of aggregation were calculated for each ionophore
(& Cq,~ Py, ○ A23187). Data are mean  standard error of the mean (SEM) from at least 5 experiments.
Fig. 5 Ionophore-induced shape change is sensitive to pre-treatment with (Cyt-D) or TPEN. (A) Representative aggregometry traces showing
clioquinol (Cq)-, pyrithione (Py)- or A23187-induced (30 µM) shape change following pre-treatment with TPEN (50 µM) or Cyt-D (10 µM). (B)
Quantitation of minimum aggregation following treatment of platelets pre-treated with TPEN (& 25 µM), Cyt-D (& 10 µM) or vehicle (& DMSO,
prior to stimulation with Cq, Py or A23187 (30 µM). Data are mean  standard error of the mean (SEM) of at least 6 experiments. Signiﬁcance is
denoted as p < 0.001, p < 0.01 or p < 0.05.
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independently of Zn2þ signals, and could indicate different
mechanisms for Zn2þ- and Ca2þ-induced shape change.
[Zn2þ]i-dependent cytoskeletal changes were further
investigated by visualizing platelet spreading on ﬁbrinogen.
TPEN-treated platelets were able to adhere to ﬁbrinogen, but
did not spread, with no visible lamellipodia or ﬁlopodia
(►Fig. 6A). Mean platelet surface coverage after 10 minutes
was 12.8  1.5 µm, compared with 22.7  1.6 µm for
untreated platelets (►Fig. 6B). Regulation of Cq-induced
shape change was investigated by assaying VASP and MLC,
which alter phosphorylation status during cytoskeletal re-
arrangements.25,26 Cq- or Py-induced shape change were
accompanied by increased phosphorylation of ser157 of
MLC, conﬁrming a role for [Zn2þ]i in the signalling process
leading to cytoskeletal changes. Unlike PGE1 treatment, VASP
did not undergo phosphorylation in response to ionophore
treatment, indicating that Zn2þ does not inﬂuence activity of
cyclic nucleotide-dependent kinases such as protein kinase A
(PKA) or protein kinase G (PKG).27
These data indicate that increases in [Zn2þ]i initiate
platelet activation events, such as shape change and aggre-
gation. To better understand the extent to which changes in
[Zn2þ]i regulate platelet activation, the inﬂuence of Cq
treatment on conventional markers of platelet activation
Fig. 6 [Zn2þ]i regulates platelet shape change, and phosphorylation of cytoskeletal regulators. Washed platelet suspensions were incubated on
ﬁbrinogen-coated coverslips following pre-treatment with 50 µM TPEN or vehicle control (DMSO). (A) Representative images of platelet
spreading. (B) Quantiﬁcation of the surface coverage by adherent platelets (○ DMSO,• 50 µM TPEN, n ¼ 3). (C) Representative Western blot
showing increased MLC phosphorylation following stimulation of platelets for 2 minutes with vehicle (DMSO), thrombin (1 U/mL), A23187
(100 µM), clioquinol (Cq) (300 µM) and pyrithione (Py) (300 µM). (D) Representative Western blot showing VASP phosphorylation following
stimulation of platelets for 2 minutes with vehicle (DMSO), prostaglandin E1 (PGE1) (1 U/mL), A23187 (100 µM), Cq (300 µM) and Py (300 µM).
VASP phosphorylation was unaffected by Zn2þ ionophore treatment. Blots are representative of three experiments. Data are means  standard
error of the mean (SEM), from at least 5 independent experiments. Signiﬁcance is denoted as p < 0.001, p < 0.01 or p < 0.05.
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was investigated. In a similar manner to thrombin and
A23187, Cq or Py stimulation (300 µM) substantially
increased platelet PAC-1 binding (59.7  5.5, 64.5  5.8,
47.3  4.1 and 37.8  5.0%, respectively, p < 0.05,
►Fig. 7A), consistent with earlier observations correlating
Cq stimulation with aggregation (►Fig. 4), and supportive of
a role for [Zn2þ]i in αIIbβ3 activation. Cq or Py increased CD63,
but not CD62P externalization (55.9  7.8 and 5.7  2.8%,
respectively, following Cq stimulation, and 50.2  2.6 and
6.9  2.2% following Py stimulation, ►Fig. 7A) indicating
that increases in [Zn2þ]i initiate dense, but not α granule,
secretion. This differed from both thrombin (CD62P:
Fig. 7 Increasing platelet [Zn2þ]i using Zn
2þ ionophores increases platelet activation markers. (A) Washed platelet suspensions were stimulated
by thrombin (Thr, 1 U/mL), clioquinol (Cq) (300 µM), pyrithione (Py) (300 µM) or A23187 (100 µM) and changes of PAC-1 (white), CD62P (grey)
and CD63 (black) binding were obtained after 60 minutes. (B) Washed platelet suspensions were stimulated by CRP-XL (1 µg/mL), U46619
(10 µM) or thrombin (1 U/mL), following pre-treatment with TPEN (50 µM), and changes of PAC-1 (white), CD62P (grey) and CD63 (black)
binding were obtained after 60 minutes. (C) Washed platelet suspensions were treated with Ca2þ or Zn2þ ionophores, or conventional platelet
agonists, prior to analysis of annexin-V binding by ﬂow cytometry. & Clioquinol (300 µM),~ pyrithione (300 µM),○ A23187 (300 µM),• CRP
(1 µg/mL),& thrombin, (1 U/mL),& vehicle (DMSO). (D) Platelet suspensions were pre-treated with the caspase inhibitor Z-VAD (~, 1 µM), the
Zn2þ chelator, TPEN (&, 25 µm) or vehicle (&) prior to stimulation with clioquinol (300 µM). ○ Unstimulated platelets. Changes in the
percentage of platelets binding to annexin-V were recorded. Washed platelets suspensions were pre-treated with Z-VAD (1 µM), or TPEN (50 µM)
prior to stimulation with conventional agonists, CRP-XL (1 µg/mL, E), U46619 (10 µM, F) or thrombin (1 U/mL, G). Changes in annexin-V binding
were monitored using ﬂow cytometry.○ Vehicle, & Z-VAD (1 µM),~ TPEN (50 µM),5 DMSO (no agonist). Data are means  standard error of
the mean (SEM) of at least 3 independent experiments. Signiﬁcance is denoted as p < 0.001, p < 0.01 or p < 0.05.
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62.9  5.5%, CD63: 48.8  3.0%) and A23187 (CD62P:
31.1  5.7%, CD63: 55.1  5.0%), which also regulate α and
dense granule release.
Further experiments were performed to assess the inﬂu-
ence of [Zn2þ]i on agonist-evoked changes in platelet activa-
tory markers. TPEN reduced increases of PAC-1, or CD63
binding in response to CRP-XL (1 µg/mL, from 55.4  4.9
to 29.0  1.5% for PAC-1 binding, and from 46.4  4.0 to
24.2  2.5% for CD63 binding, p < 0.05), U46619 (10 µM,
from 36.2  2.8 to 16.5  1.2% for PAC-1 binding, and from
21.9  3.6 to 10.7  1.3% for CD63 binding, p < 0.05) or
thrombin (1 U/mL, from 64.6  5.2 to 32.1  3.6% for PAC-
1 binding, and from 46.8  3.8 to 17.6  2.3% for CD63
binding, p < 0.05), but had no effect on agonist-evoked
CD62P increases (►Fig. 7B). This provides further support
for a role of [Zn2þ]i in differentially regulating platelet
granule secretion.
Extracellular Zn2þ signalling and agonist-induced changes
in [Zn2þ]i have both been linked to apoptosis and related
responses in nucleated cells.28–31 However, the role of Zn2þ
in PS exposure during platelet activation has yet to be
studied. To investigate the inﬂuence of [Zn2þ]i on PS expo-
sure, platelets were treated with ionophores, and annexin-V
binding was quantiﬁed in real time. Increasing platelet
[Zn2þ]i with Cq (300 µM) resulted in a concurrent increase
in annexin-V binding. PS exposure evolvedmore slowly with
Zn2þ ionophore treatment than A23817, but reached similar
plateau levels (90.0  0.9 and 88.6  2.7% for Cq and
A23187, respectively, ►Fig. 7C), indicating that most plate-
lets in the population were annexin-V positive. This differed
in responses to conventional agonists, thrombin and CRP-XL,
which induced PS exposure in a sub-set of platelets
(35.0  6.2 and 34.4  6.2%, respectively). Cq-induced
annexin-V bindingwas sensitive toTPEN (6.6  6.3% positive
platelets at 60 minutes) conﬁrming a role for Zn2þ. Further-
more, pre-treatment with the caspase inhibitor, Z-VAD,
abrogated Cq-induced PS exposure (53.6  4.7% at 60 min-
utes, p < 0.05, ►Fig. 7D). The inﬂuence of Zn2þ on agonist-
evoked annexin-V binding was also investigated. Consistent
with theﬁndings of Cohen et al,32we observed a reduction in
agonist-evoked PS exposure in the presence of Z-VAD (1 µM)
(from 34.4  2.9 to 23.1  2.0% following stimulation with
1 µg/mL CRP-XL, from 24.4  1.8 to 15.2  2.0% following
stimulation with 10 µM U46619 and from 32.5  4.8 to
21.2  2.4% following stimulation with 1 U/mL thrombin,
►Fig. 7E–G, p < 0.05). Similar reductions of annexin-V bind-
ing in TPEN-treated platelets were observed following sti-
mulation by CRP-XL (26.3  0.9%, p < 0.05), or U46619
(21.4  2.7%, p < 0.05). However, TPEN did not affect throm-
bin-mediated annexin-V binding (28.3  4.6%, ns). These
data are consistent with a role for Zn2þ in agonist-evoked
PS exposure.
Discussion
The role of Zn2þ as a secondary signalling molecule has
received little research interest, possibly owing to its relatively
low resting cytosolic levels (pM, compared with nM concen-
trations of Ca2þ). Zn2þ is present in granules of nucleated cells,
and inplateletα granules. It also associateswith thiol-contain-
ing proteins such as metallothioneins, which are also present
in platelets.33 The transition between protein- or membrane-
bound Zn2þ and labile Zn2þ in the cell cytosol has been
demonstrated in multiple cell systems, and increases in labile
[Zn2þ]i have been correlated with phenotypic changes. Here,
we show for the ﬁrst time that agonist-evoked stimulation of
platelets in vitro results in increases of [Zn2þ]i.While requiring
further conﬁrmation, such behaviour is consistent with a role
of Zn2þ as a secondary messenger. Zn2þ ﬂuctuations were
apparent in the presence of extracellular CaCl2, supporting a
physiological role for this effect. We conﬁrm the nature of the
ﬂuorescent signal using the high afﬁnity Zn2þ chelator TPEN.
TPEN was also used to probe the role of Zn2þ in functional
responses to agonist stimulation. Owing to its afﬁnity for Zn2þ,
use of TPEN here is not only likely to abrogate agonist-evoked
increases in [Zn2þ]i, but could also strip metalloproteins of
Zn2þ co-factors.34 Thus, conclusions drawn from the use of
TPENmaynotonly reﬂect abrogationofagonist-evoked [Zn2þ]i
increases. [Zn2þ]i increases were observed in platelets follow-
ing stimulationviaGpVI andTP, butnot via PAR, indicating that
different signalling pathways link to [Zn2þ]i release. Signalling
via GpVI differs from that of TP or PAR G-protein-coupled
receptors, in that it results in tyrosine phosphorylation of
platelet proteins (such as Syk and LAT), leading to activation of
PI3K and PLCγ2. Conversely, PAR and TP signal through G-
protein-dependent routes to activate Rho-GEF and PLCβ. It is
likely that [Zn2þ]i increases are regulatedbysignalling proteins
that are not shared byGpVI and thrombinpathways. However,
the different outcomes following PAR and TP-dependent sig-
nalling are harder to reconcile, as both receptors couple to
similar signalling pathways that involve Gα12/13 and Gαq.
We show that the platelet redox state effects [Zn2þ]i ﬂuc-
tuations in a similar manner to nucleated cells.35,36 CRP-XL-
and U46619-evoked elevations of [Zn2þ]i were sensitive to
antioxidants, and could be enhanced by H2O2. Zn2þ binding to
thiols (e.g.metallothioneins) is redox-sensitive and changes of
redox state lead to release of Zn2þ into the labile pool in
nucleated cells.37 Given that modulation of the platelet redox
state led to a rapid and sustained rise of [Zn2þ]i, it is possible
that platelet Zn2þ-binding proteins represent a store for these
cations. Interestingly, Ca2þ signalling was unaffected by redox
changes, suggesting that these ionsaredifferentially regulated.
Indeed, the predominant Ca2þ store is the dense tubular
system, which performs a similar role to the endoplasmic
reticulum in nucleated cells. It is therefore likely that intra-
platelet Zn2þ is stored by Zn2þ-binding proteins and becomes
liberated upon agonist stimulation. However, we did not
observe increases of [Zn2þ]i following thrombin stimulation,
which has been shown to induce similar levels of ROS activa-
tionas collagenactivation.18,38Onepossible explanationcould
bethat the largerCa2þ signalgeneratedby thrombinnegatively
regulates Zn2þrelease.
We examined the inﬂuence of [Zn2þ]i on activatory pro-
cesses using membrane permeable Zn2þ-speciﬁc iono-
phores, Py and Cq, which have been widely used to model
increases in [Zn2þ]i. Stimulation with either ionophore
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resulted in increases in [Zn2þ]i, with a greater signal obtained
with Cq. Neither ionophore produced increases in Fluo-4
ﬂuorescence, indicating a negligible afﬁnity for [Ca2þ]i.
Conversely, stimulation with the Ca2þ ionophore A23187
produced rapid increases in [Ca2þ]i, but did not affect [Zn2þ]i.
Investigation of cation responses in cells depends heavily on
the speciﬁcity of reagents for their cognate ions. By showing
that A23187 initiates a Ca2þ response which is not detected
by Fz-3, we demonstrate that Fz-3 ﬂuorescence increases are
directly attributable to changes in [Zn2þ]i, and are not
inﬂuenced by [Ca2þ]i. This is further supported by our
observation that TPEN does not affect Fluo-4 ﬂuorescence,
which also provides evidence that agonist-evoked Ca2þ
signalling does not depend on [Zn2þ]i signals. This observa-
tion raises questions about the relative roles of Ca2þ and Zn2þ
in platelet activation, as both target similar proteins, includ-
ing PKC, calmodulin and CamKII.4Unlike agonist stimulation,
ionophore-induced [Zn2þ]i increases were not sensitive to
anti-oxidant treatment. Furthermore, the extent of [Zn2þ]i
following ionophore stimulation was greater than that
observed for agonists, indicating that ionophores liberate
Zn2þ from stores that are not accessible to agonist-evoked
signallingmechanisms. Such stores could include α granules,
which are known to contain Zn2þ.20 Our use of ionophores
here to model [Zn2þ]i increases while providing information
on Zn2þ-dependent mechanisms, is therefore unlikely to
fully represent the physiological situation.
Cytoskeletal re-arrangements are primary steps in plate-
let activation. Zn2þ ionophore stimulation resulted in a
demonstrable shape change, which was abrogated following
Cyt-D treatment, verifying it as a biological, rather than
chemical, response. Furthermore, platelet spreading on ﬁbri-
nogen was abrogated following [Zn2þ]i chelation. While not
correlating [Zn2þ]i ﬂuctuations with shape change, these
data provide support for a role of Zn2þ in activation-depen-
dent cytoskeletal re-arrangements. Zn2þ is an important
regulator of the cytoskeleton in nucleated cells.39,40 Zn2þ
regulates tubulin polymerization leading to nuclear trans-
port of transcription factors in neuronal cells,41 and has been
shown to regulate the actin cytoskeleton, focal adhesion
dynamics and cell migration in PC-3 and HeLa cells,35 where
Zn2þ chelation supresses ﬁlopodia formation and results in
the loss of stress ﬁbres. Conversely, treatment with Py
increased ﬁlopodia formation, supressed stress ﬁbres and
decreased the number and size of focal adhesions.35 Thus,
Zn2þ is likely to play similar important roles in platelet
cytoskeletal re-arrangements. We show that raising [Zn2þ]i
results in increases in MLC phosphorylation. MLCK is cano-
nically activated via Ca2þ-mediated activation of calmodu-
lin.42 As other calmodulin-dependent kinases have been
shown to be modulated by Zn2þ, it is possible that Zn2þ is
able to substitute for Ca2þ, initiating MLCK activation.43
Absence of phosphorylation of VASP indicates that increases
in [Zn2þ]i do not inﬂuence the activity of cyclic nucleotide-
dependent kinases such as PKG or PKA.
Ionophore-induced elevation of [Zn2þ]i increased PAC-1
binding, supporting our aggregometry data (►Fig. 4), and
supportive of role for Zn2þ in regulating αIIbβ3 activity
(►Fig. 6). Interestingly, [Zn2þ]i increases resulted in the
externalization of CD63, but not CD62P, supporting a role
for Zn2þ in regulating α, but not dense granule release.
Further experiments using TPEN in conjunction with conven-
tional platelet agonists provides support for a role for [Zn2þ]i
in αIIbβ3 activation and dense granule secretion, but not α
granule secretion (►Fig. 7B). Distinct signalling pathways
contribute to differential release of α and dense granules,
and while the exact mechanism is poorly understood, our
work provides evidence for a role for Zn2þ in these pro-
cesses.44,45 While these studies show that Zn2þ ﬂuctuations
correlate with platelet behaviour, it should be noted that the
physiological relevance of the ionophore-evoked [Zn2þ]i rises
are unclear and that further work will be required to establish
the signiﬁcance of Zn2þ-dependent secondary signalling in
vivo. Upon stimulation with conventional agonists, a sub-set
of platelets adopt pro-coagulant phenotypes, elevating [Ca2þ]i
and externalizing PS. Extracellular Zn2þ signalling, agonist-
induced changes in [Zn2þ]i and Zn2þ ionophore treatment
have all been linked to apoptosis and related responses in
nucleated cells.30,31,46–50 Here, we demonstrate that iono-
phore or agonist-evoked increases in platelet [Zn2þ]i results in
PS exposure, consistent with the development of a pro-
coagulant phenotype. Interestingly, while CRP-XL and
U46619 evoked PS exposure was sensitive to Zn2þ chelation,
thrombin stimulation was not. This provides further support
for a role of Zn2þ following GpVI and TPα signalling, but not
via PARs. Unlike conventional agonists, Cq stimulation
resulted in PS exposure in a majority of platelets. This may
indicate that agonist-evoked Zn2þ signals are stimulated in
only a sub-set of platelets, which then proceed to become pro-
coagulant. As previously shown (►Fig. 3), Cq stimulation did
not induce increases in [Ca2þ]i, so Cq-dependent PS exposure
is independent of [Ca2þ]i. Platelet PS exposure has been
attributed to both caspase 3-dependent and independent
mechanisms.51,52 Cq-dependent PS exposure is partially
abrogated by Z-VAD pre-treatment suggesting a partial role
for caspase activity in this process.
In conclusion, this study provides the ﬁrst evidence for
agonist-evoked increases of [Zn2þ]i in platelets.While requir-
ing further conﬁrmation, such behaviour is consistent with a
role of Zn2þ as a secondary messenger. Increases in [Zn2þ]i
are sensitive to the redox state, indicative of a role for redox
in agonist-evoked Zn2þ signalling. Modelling increases of
[Zn2þ]i using Zn2þ-speciﬁc ionophores reveal a functional
role for [Zn2þ]i in platelet activatory changes. [Zn2þ]i signal-
ling contributes to key activation-related platelet responses,
including shape change,αIIbβ3 activation andgranule release.
The mechanism by which Zn2þ affects these processes is
currently unknown, but could be attributable to changes in
activity of Zn2þ-binding enzymes. These data indicate a
hitherto unknown role for labile [Zn2þ]i during platelet
activation, which has implications for our understanding of
signalling responses in platelets. While this work does not
address the physiological relevance of this process, a better
understanding of Zn2þ signalling may be of signiﬁcance to
the role of platelets in thrombotic disorders such as heart
attack and stroke.
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Furthermore, as they are readily available primary cells,
platelets could be used as a model to better understand Zn2þ
signalling in other mammalian cells.
What is known about this topic?
• Zinc is an intracellular secondary messenger in
nucleated cells.
• Agonist-dependent ﬂuctuations of zinc in platelets,
leading to functional changes, have yet to be
demonstrated.
What does this paper add?
• Intra-platelet zinc increases in concentration following
agonist stimulation.
• Increases in zinc regulate activatory processes, includ-
ing aggregation, shape change and PS exposure.
• This is the ﬁrst work to demonstrate a role for zinc in
agonist-dependent signal transduction in platelets.
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